Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin

Terminated

• Conditions: Metastatic Melanoma; Nausea

• Registration Number: NCT00716560
• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Brief Summary

The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.

Detailed Description

Questionnaires are completed on week of chemotherapy treatment referred to as Dartmouth regimen.

Study Timeline

• Study Start: 2005-05
• Study First Submitted: 2008-07-14
• Study First Submitted QC: 2008-07-14
• Study First Posted: 2008-07-16
• Primary Completion: 2009-03
• Study Completion: 2009-03
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-01
• Last Update Posted: 2025-05-06

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• confirmed diagnosis metastatic melanoma
• 18 years and older
• undergoing chemotherapy with Dartmouth regimen
• medically stable to receive chemotherapy per physical and clinical laboratory tests

Exclusion Criteria

• No medical conditions that interfere with assessment of nausea and vomiting during chemotherapy
• No cognitive disorder that impairs symptom assessment
• No other investigational agent
• Inability to swallow medications for nausea and vomiting
• No gastric outlet obstruction

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine incidence of nausea when receiving Dartmouth regimen chemotherapy for metastatic melanoma	Week of treatment

Secondary Outcome Measures

Name	Time	Method
Assess the impact of systemic chemotherapy with Dartmouth regimen on quality of life of patients	week of treatment

Trial Locations

Locations (1)

Thomas Jefferson University Hospital; 🇺🇸 Philadelphia, Pennsylvania, United States